PACE-CME

Nephroprotective effects with SGLT2i in CKD patients

Nephroprotective effects with SGLTi in CKD patients
RestartResume
3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD
  • Overview

    ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

  • Educational information

    This video was recorded during the ESC Congress 2020.

  • Faculty

    Prof. Hiddo Heerspink, PhD is a clinical pharmacologist at the University Medical Center Groningen (UMCG) in the Netherlands

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    Read our summary of the DAPA-CKD trial

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free